Hepatitis delta: Epidemiology, diagnosis and management 36 years after discovery

Current Gastroenterology Reports

Volumn 16, Issue 1, 2014, Pages

  Noureddin, Mazen ^a   Gish, Robert ^a,b,c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LLC   (United States)

^c ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEVADA   (United States)

Author keywords

Chronic hepatitis; Cirrhosis; Hepatitis; Hepatitis delta virus; Interferon alpha; RNA

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; FAMCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTERFERON; LAMIVUDINE; LONAFARNIB; MYCLURDEX; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; UNCLASSIFIED DRUG;

ARTICLE; AUSTRALIA; AWARENESS; DELTA AGENT HEPATITIS; EARLY DIAGNOSIS; EPIDEMIC; EUROPE; HEPATITIS B; HIGH RISK POPULATION; HUMAN; LIVER CIRRHOSIS; MONOTHERAPY; NONHUMAN; PATIENT EDUCATION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING TEST; SEXUAL TRANSMISSION; UNITED STATES; VIRUS LOAD; DISEASE TRANSMISSION; HEPATITIS DELTA VIRUS; ISOLATION AND PURIFICATION; REVIEW; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPATITIS D; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON-ALPHA; PREVALENCE; TREATMENT OUTCOME;

EID: 84888237874     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-013-0365-x     Document Type: Article

References (63)

1. Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18:997-1003. (Pubitemid 8263407)
2. Rizzetto M, Canese MG, Gerin JL, et al. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis. 1980;141:590-602. (Pubitemid 10109828)
3. RizzettoM, Hoyer B, CaneseMG, et al. delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A. 1980;77: 6124-8. (Pubitemid 11206354)
4. Rizzetto M, Purcell RH, Gerin JL. Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet. 1980;1:1215-8.
5. Flores R, Ruiz-Ruiz S, Serra P. Viroids and hepatitis delta virus. Semin Liver Dis. 2012;32:201-10.
6. Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine. 1990;8(Suppl):S10-4. discussion S21-13. (Pubitemid 20154748)
7. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31-40.
8. Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis. 2012;32:211-9.
9. Gish RG, Yi DH, Kane S, et al. Coinfection with Hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013;28(9):1521-5.
10. Kucirka LM, Farzadegan H, Feld JJ, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202:845-52.
11. Stroffolini T, Almasio PL, Sagnelli E, et al. Evolving clinical landscape of chronic hepatitis B: a multicenter Italian study. J Med Virol. 2009;81:1999-2006.
12. Alvarado-MoraMV, Locarnini S, Rizzetto M, et al.An update onHDV: virology, pathogenesis and treatment. Antivir Ther. 2013;18:541-8.
13. Dunford L, CarrMJ, Dean J, et al. A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. PloS One. 2012;7:e39027.
14. Braga WS, Castilho Mda C, Borges FG, et al. Hepatitis D virus infection in the Western Brazilian Amazon - far from a vanishing disease. Rev Soc Bras Med Trop. 2012;45:691-5.
15. Lunel-Fabiani F,MansourW, Amar AO, et al. Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: A cross sectional study. J Infect. 2013;67(5):448-57.
16. Bakhshipour A, Mashhadi M, Mohammadi M, et al. Seroprevalence and risk factors of hepatitis delta virus in chronic hepatitis B virus infection in Zahedan. Acta Med Iran. 2013;51:260-4.
17. Amini N, Alavian SM, Kabir A, et al. Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis. Hepat Mon. 2013;13:e8210.
18. Nguyen VT, McLaws ML, Dore GJ. Highly endemic hepatitis B infection in ruralVietnam. JGastroenterol Hepatol. 2007;22:2093-100.
19. TranHT,UshijimaH, QuangVX, et al. Prevalence of hepatitis virus types B through E and genotypic distribution of HBVand HCV in Ho Chi Minh City, Vietnam. Hepatol Res. 2003;26:275-80. (Pubitemid 37184515)
20. Gomaa NI, Metwally LA, Nemr N, et al. Seroprevalence of HDV infection in HBsAg positive population in Ismailia, Egypt. Egypt J Immunol. 2013;20:23-8.
21. Saravanan S, Madhavan V, Velu V, et al. High prevalence of hepatitis delta virus among patients with chronic hepatitis B virus infection and HIV-1 in an intermediate hepatitis B virus endemic region. J Int Assoc Provid AIDS Care. 2013. doi:10.1177/ 2325957413488166.
22. Manesis EK, Vourli G, Dalekos G, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59(5):949-56.
23. Ho E, Deltenre P, Nkuize M, et al. Coinfection of hepatitis B and hepatitis delta virus in Belgium: a multicenter BASL study. Prospective epidemiology and comparison with HBV monoinfection. J Med Virol. 2013;85:1513-7.
24. William Tong CY, Asher R, Toby M, et al. A re-assessment of the epidemiology and patient characteristics of hepatitis D virus infection in inner city London. J Infect. 2013;66:521-7.
25. Popescu GA, Otelea D, Gavriliu LC, et al. Epidemiology of hepatitis D in patients infected with hepatitis B virus in bucharest: a cross-sectional study. J Med Virol. 2013;85:769-74.
26. Rivas P, Herrero MD, Poveda E, et al. Hepatitis B, C, and D and HIVinfections among immigrants from Equatorial Guinea living in Spain. Am J Trop Med Hyg. 2013;88:789-94.
27. Shadur B, Maclachlan J, Cowie B. Hepatitis D virus in Victoria 2000-2009. Intern Med J. 2013;43(10):1081-7.
28. Farci P. Delta hepatitis: an update. J Hepatol. 2003;39 Suppl 1: S212-9. (Pubitemid 37222675)
29. Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32:228-36.
30. Kew MC. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. J Viral Hepat. 2013;20:149-57.
31. Olivero A, Smedile A. Hepatitis delta virus diagnosis. Semin Liver Dis. 2012;32:220-7.
32. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73-85.
33. Katsoulidou A, Manesis E, Rokka C, et al. Development and assessment of a novel real-time PCR assay for quantitation of hepatitis D virus RNA to study viral kinetics in chronic hepatitis D. J Viral Hepat. 2013;20:256-62.
34. Brichler S, Le Gal F, Butt A, et al. Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia. Clin Gastroenterol Hepatol. 2013;11:734-40.
35. Kodani M, Martin A, Mixson-Hayden T, et al. One-step real-time PCR assay for detection and quantitation of hepatitis D virus RNA. J Virol Methods. 2013;193:531-5.
36. Calle Serrano B, Heidrich B, Homs M, et al. Development and evaluation of a Baseline Event-Anticipation (BEA)-score forhepatitis delta. Hepatology. 2011;54:444.
37. Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. 2012;32:237-44.
38. Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. 2005;22:227-32. (Pubitemid 41153065)
39. Garripoli A, Di Marco V, Cozzolongo R, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver. 1994;14:154-7. (Pubitemid 24221772)
40. Yurdaydin C, Bozkaya H, Gurel S, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol. 2002;37:266-71. (Pubitemid 34833090)
41. Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. Hepatology. 1999;30:546-9. (Pubitemid 29357523)
42. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322-31.
43. Heidrich B, Manns MP, Wedemeyer H. Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep. 2013;15:31-8.
44. Heidrich B, Yurdaydin C, Kabacam G, et al. Long-term followup after Peg-IFNa2a-based therapy of chronic hepatitis delta. J Hepatol. 2013;58:S20.
45. Farci P,Mandas A, Coiana A, et al. Treatment of chronic hepatitisD with interferon alfa-2a. N Engl J Med. 1994;330:88-94.
46. Lamers MH, Kirgiz OO, Heidrich B, et al. Interferon-alpha for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther. 2012;17:1029-37.
47. Alavian SM, Tabatabaei SV, Behnava B, et al. Standard and pegylated interferon therapy of HDVinfection: a systematic review and meta- analysis. J Res Med Sci. 2012;17:967-74.
48. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713-20. (Pubitemid 44433728)
49. OrmeciN, Bolukbas F, Erden E, et al. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24months. Hepatogastroenterology. 2011;58:1648-53.
50. Kabacam G, Dalekos GN, Cakaloglu Y, et al. Pegylated interferonbased treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol. 2012;23:560-8.
51. Sanchez-Tapias JM, Mas A, Costa J, et al. Recombinant alpha 2cinterferon therapy in fulminant viral hepatitis. J Hepatol. 1987;5: 205-10. (Pubitemid 17144753)
52. Heller T, Hoofnagle JH. Denying the wolf access to sheep's clothing. J Clin Invest. 2003;112:319-21. (Pubitemid 38063757)
53. Glenn JS, Watson JA, Havel CM, et al. Identification of a prenylation site in delta virus large antigen. Science. 1992;256: 1331-3.
54. Lutgehetmann M, Mancke LV, Volz T, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55:685-94.
55. Mahtab MA, Bazinet M, Vaillant A. REP 9 AC: a potent HBsAg release inhibitor that can rapidly restore immunocompetence in patients with chronic hepatitis B. Hepatology. 2010;52:559A-60.
56. Mahtab MA, Bazinet M, Vaillant A. REP 9AC: a potent HBsAg release inhibitor that can rapidly restore immunocompetence in patients with chronic hepatitis B. The 61st Annual Meeting of the American Association for the Study of Liver Diseases; Boston, Massachusetts; Oct 29-Nov 2, 2010.
57. Wooddell CI, Rozema DB, HossbachM, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther. 2013;21:973-85.
58. Grabowski J, Yurdaydin C, Zachou K, et al. Hepatitis D virusspecific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver Int. 2011;31: 1395-405.
59. Roethle PA, McFadden RM, Yang H, et al. Identification and optimization of pteridinone toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis. J Med Chem. 2013;56(18):7324-33.
60. Ciancio A, RizzettoM. Chronic hepatitis D at a standstill: where do we go from here? Nat Rev Gastroenterol Hepatol. 2013. doi:10. 1038/nrgastro.2013.164.
61. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine+interferon vs interferon. J Viral Hepat. 2008;15:314-21. (Pubitemid 351326903)
62. Yurdaydin C, Bozkaya H, Karaaslan H, et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J Viral Hepat. 2007;14:812-6. (Pubitemid 47561587)
63. Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RTPCR for follow-up. Hepatology. 2006;44:728-35. (Pubitemid 44433730)